Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome

AUTOR(ES)

Polat, Asude Kara, Belli, Asli Akin, Karakus, Volkan, Dere, Yelda

FONTE

An. Bras. Dermatol.

DATA DE PUBLICAÇÃO

2017

RESUMO

Abstract Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case of myelodysplastic syndrome with urticarial vasculitis due to deferasirox therapy. Drug eruption was been confirmed by means of a challenge test, together with histopathological and clinical findings. To the best of our knowledge, we report the first case of deferasirox-induced urticarial vasculitis. Physicians should be aware of the possibility of urticarial vasculitis on deferasirox therapy and the fact that the discontinuation of the drug generally results in improvement.

Documentos Relacionados

• Meningococcal meningitis in a patient with urticarial vasculitis: is there a link?
• Primary myelodysplastic syndrome with complex chromosomal rearrangements in a patient with Klinefelter's syndrome.
• Digital vasculitis after splenectomy in a patient with Felty's syndrome.
• Urticarial vasculitis and syndromes in association with connective tissue diseases.
• Bartonella henselae bacteremia diagnosed post-mortem in a myelodysplastic syndrome patient